These are two different tools, not two grades of the same treatment. For some cancers immunotherapy is clearly superior; for others chemotherapy remains the backbone of curative treatment. Many modern regimens use both together.
The core differences
- Mechanism — chemotherapy kills dividing cells; immunotherapy unblocks the immune response
- Speed — chemotherapy often shrinks tumours faster; immune responses may take weeks to months
- Duration of benefit — immune responses, when they occur, can be more durable
- Side effects — low counts, nausea and hair loss versus immune-related organ inflammation
- Eligibility — chemotherapy is broadly applicable; immunotherapy depends on biomarker testing
- Cost — immunotherapy is generally significantly more expensive
How the decision is actually made
The choice follows the cancer type, stage, biomarker results, previous treatment, organ function and the patient's general fitness. In curative settings such as acute leukaemia, testicular cancer or many lymphomas, chemotherapy is the treatment that cures. In advanced lung, kidney or bladder cancer with favourable biomarkers, immunotherapy is often preferred or added.
Combining both
In several advanced cancers, chemotherapy plus immunotherapy performs better than either alone — chemotherapy exposes tumour antigens, which can make the immune attack more effective. Combination regimens are now standard in defined situations.
Read next
Medical disclaimer: This page is general health information, not medical advice. Cancer treatment decisions depend on your reports, stage and overall health. Please consult a qualified oncologist before acting on anything you read here.